#285 Should a ‘flozin be chosen to play a part for a failing heart?
CLINICAL QUESTION
What is the role of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with chronic heart failure with reduced ejection fraction?
BOTTOM LINE
SGLT2i reduce mortality, heart failure hospitalizations, and improve quality of life when added to other medications in patients with heart failure with reduced ejection fraction, with or without diabetes. For every 100 patients treated with an SGLT2i for ~1.5 years, ~2 fewer will die, ~4 fewer will be hospitalized for heart failure, and ~7 will have improved quality of life (by 8 months) compared to placebo.
Reading Tools for Practice Article can earn you MainPro+ Credits
Join NowAlready a CFPCLearn Member? Log in
EVIDENCE
Two industry-funded, randomized, placebo-controlled trials1,2 of patients with heart failure and ejection fraction ≤40% (mainly NYHA class 2-3, 47% with diabetes, average systolic blood pressure 122 mm Hg, 65% on combination betablocker/renin-angiotensin system blocker/mineralocorticoid receptor antagonist3). Results statistically different unless indicated.
- DAPA-HF:1 4744 patients, dapagliflozin 10mg daily.
- At 18 months:
- Mortality: 11.6% versus 13.9% (placebo), number needed to treat (NNT)=44.
- Heart failure hospitalization: 9.7% versus 13.4% (placebo), NNT=27.
- At 8 months:
- 58.3% versus 50.9% (placebo) achieved minimal important improvement in quality of life (≥5 points on 100-point scale), NNT=14.
- Adverse events: No difference.
- At 18 months:
- EMPEROR-Reduced:2 3730 patients, empagliflozin 10mg daily. At 16 months:
- Mortality: 13.4% versus 14.2% (placebo), not statistically different.
- Heart failure hospitalization: 13.2% versus 18.3% (placebo), NNT=20.
- Adverse events:
- Genital infections: 1.7% versus 0.6% (placebo), NNH=91.
- One meta-analysis4 including both trials:
- Reduction in mortality (NNT=61) and heart failure hospitalization (NNT=24).
- Similar efficacy in those with or without diabetes, and with or without sacubitril-valsartan.
- SGLT2i efficacy comparable to other heart failure medications:5,6
- Mortality: Relative risk reduction ~13% (others ~16-35%).
- Heart failure hospitalization: Relative risk reduction ~30% (others ~20-35%).
- Unlike other heart failure medications, SGLT2i do not seem to cause significant hypotension or electrolyte abnormalities.1,2,4
- Canadian guidelines7 recommend SGLT2i for patients with “mild to moderate” heart failure, though sequence not specified (e.g. whether to consider SGLT2i prior to sacubitril-valsartan).
- Splitting empagliflozin 25mg in half=12.5 mg (trial dose=10 mg) cuts cost in half (to ~$560/year).8
Latest Tools for Practice
#378 Tony Romo-sozumab: Winning touchdown in osteoporosis or interception for the loss?
What is the efficacy and safety of romosozumab in postmenopausal women with osteoporosis?
#377 How to slow the flow IV: Combined oral contraceptives
In premenopausal heavy menstrual bleeding due to benign etiology, do combined oral contraceptives (COC) improve patient outcomes?
#376 Testosterone supplementation for cis-gender men: Let’s (andro-)pause for a moment (Update)
What are the benefits and harms of testosterone supplementation in healthy cis-gender men or those with age-related low testosterone?
loosing glucose in urine helps to control DM and overweight in Diabetic patients, but for non Diabetic patients with low BMI, can SGLT2i cause issue of malnutrition ?
I was an early adopter of SGLT2 inhibitors for this indication into my practice. One other benefit that is important to consider is that they do not disturb serum sodium or potassium.
good tip in saving money with halting the pill
I have started using Flozins for CHF patients in my practice